Clinical Trials Browser

INDUSTRY × IFL protocol × Gastrointestinal × Clear all

NCT06663319 2026-04-13

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

Phase 1 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT03798626 2026-04-01

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1 Completed

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT04929223 2026-03-31

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07221357 2026-03-31

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06179160 2026-03-16

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07446322 2026-03-04

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Ras-mutated Metastatic Colorectal Cancer

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Phase 1 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07323576 2026-02-09

INAVO-CRC

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT06106308 2026-01-12

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05786924 2025-11-20

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Phase 1/2 Recruiting

CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

NCT05480306 2025-08-03

DeFianCe

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT05848739 2025-05-11

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT05004350 2025-04-15

NAUTICALCRC

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT03597581 2025-04-03

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Phase 1 Terminated

GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT04952753 2025-03-26

daNIS-3

Phase 2 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT04256707 2025-03-19

SPRINT

Phase 1/2 Completed

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03829410 2025-03-04

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Phase 1/2 Completed

68 enrolled 21 charts

Gastrointestinal

Colorectal Neoplasms

NCT05087992 2025-02-19

A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

Phase 1 Completed

13 enrolled 17 charts

Gastrointestinal

Gastrointestinal Neoplasms, Neoplasm Metastasis

NCT05593328 2025-01-10

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02563002 2024-10-03

KEYNOTE-177

Phase 3 Completed

307 enrolled 16 charts 3 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05084859 2024-08-09

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Phase 1 Terminated

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05039944 2024-07-18

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Phase 2 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT03250832 2024-04-11

CITRINO

Phase 1 Completed

111 enrolled 48 charts

GastrointestinalGynecologicThoracic

Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT04446793 2024-02-12

Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

No longer available

Gastrointestinal

Colorectal Neoplasms

NCT01946074 2023-12-15

A Study of ABT-165 in Subjects With Solid Tumors

Phase 1 Completed

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT01133990 2023-11-07

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Phase 1/2 Terminated

5 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT01347645 2023-06-22

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Phase 1/2 Terminated

82 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT05684211 2023-02-01

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT03082209 2022-12-09

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Phase 1 Completed

GastrointestinalLymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT01326000 2022-11-17

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT00339183 2022-09-23

Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

Phase 3 Completed

1,186 enrolled 18 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT03454620 2022-03-03

A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04247256 2022-03-02

A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI

Phase 1/2 Unknown

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT03692429 2020-11-20

alloSHRINK

Phase 1 Recruiting

Gastrointestinal

Unresectable Metastatic Colorectal Cancer

NCT02482441 2020-08-11

A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

NCT03035253 2020-08-11

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Phase 1 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT00508404 2019-11-19

Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer

Phase 2 Completed

154 enrolled 18 charts

Gastrointestinal

Colorectal Neoplasms

NCT02568046 2019-03-26

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

Phase 1/2 Terminated

10 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT02605044 2019-02-11

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Phase 3 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT02726334 2019-01-16

A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.

Phase 1 Terminated

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02305758 2018-11-20

Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Phase 2 Completed

130 enrolled 12 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00115765 2018-10-17

PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

Phase 3 Completed

1,053 enrolled 25 charts

Gastrointestinal

Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00551213 2018-08-24

A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

Phase 2 Completed

67 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT01571284 2018-04-17

Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Phase 3 Completed

781 enrolled 28 charts

Gastrointestinal

Colorectal Cancer Metastatic

NCT00636610 2017-06-08

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

Phase 2 Completed

199 enrolled 8 charts

Gastrointestinal

Colorectal Neoplasms

NCT00813605 2016-10-27

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT01085331 2016-10-19

MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

Phase 1/2 Terminated

16 enrolled 18 charts

Gastrointestinal

Colorectal Neoplasms

NCT00454116 2016-10-07

A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

Phase 2 Completed

106 enrolled 8 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms